Back

Discussion and summary - LDL-c: done deal, next epigenetics? .

25 August 2018 (16:25 - 16:30)
Organised by:
Congress Presentation Part of: LDL-c: done deal, next epigenetics? (EBAC Accredited) Secondary Prevention ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Ulrich Laufs

University Hospital Leipzig, Leipzig (Germany)

4 More presentations in this session

Presentation thumbnail
Introduction - LDL-c: done deal, next epigenetics?
Professor U. Laufs (Leipzig, DE)
Presentation thumbnail
The real residual risk in patients with cardiovascular disease and diabetes: the promise of epigenetics.
Professor E. Stroes (Amsterdam, NL)
Presentation thumbnail
Understanding epigenetics - The potential rationale for BET inhibition in management of cardiovascular disease.
Doctor J. Plutzky (Boston, US)
Presentation thumbnail
A clinical view on BET inhibition in targeting residual risk in cardiovascular disease and diabetes.
Professor K. Ray (London, GB)

Access the full session

Session thumbnail
LDL-c: done deal, next epigenetics? (EBAC Accredited)

The Event

Event poster

ESC Congress 2018

25 August 2018 16:25 CET
You may be interested in
thumbnail
Webinar
Personalised secondary prevention post-ACS: the role of biomarkers
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources